LESCOL 94% SALES GROWTH WORLDWIDE SHOWS VITALITY OF LIPID-LOWERING MARKET; MERCK's ZOCOR UP 79% IN U.S. TO $375 MIL., BUT 1ST QUARTER LAGS 4TH QUARTER
Strong first quarter sales figures for Novartis' Lescol (fluvastatin) exemplify the vitality of the cholesterol-lowering market during the launch period for the new Warner-Lambert/Pfizer entry Lipitor and in anticipation of the potential mid-year entry of Bayer's cerivastatin.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth